GSK2801
CAS No. 1619994-68-1
GSK2801( GSK2801 | GSK-2801 | GSK 2801 )
Catalog No. M17344 CAS No. 1619994-68-1
GSK2801 is an effective, specific and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd: 136 nM) and BAZ2B(Kd: 257 nM) bromodomains.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 35 | In Stock |
|
| 5MG | 54 | In Stock |
|
| 10MG | 71 | In Stock |
|
| 25MG | 162 | In Stock |
|
| 50MG | 291 | In Stock |
|
| 100MG | 484 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK2801
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK2801 is an effective, specific and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd: 136 nM) and BAZ2B(Kd: 257 nM) bromodomains.
-
DescriptionGSK2801 is a A Selective Chemical Probe for BAZ2B/A bromodomains. BAZ2A/B belong to a family of ubiquitously expressed bromodomain containing proteins. Proteins of the BAZ family are characterized by a carboxy-terminal bromodomain adjacent to a PHD finger and a WACZ motif. In addition four other conserved motifs are typically found in the N-terminus of BAZ family members, namely the LH motif (a leucine-rich helical domain), the ZB2 motif and the BAZ 1 and BAZ 2 motifs. Little is known about the biological function of BAZ2B but it has been suggested to regulate nucleosome mobilization by the ATP-dependent chromatin remodeling factor ISWI.
-
In VitroGSK2801 binds TAF1L(2) with an affinity KB of 0.31μM (KD: 3.2 μM) and a binding enthalpy change ΔH of ?8.6 kcal/mol. ITC experiments using the bromodomain of BRD9 results in the determination of an affinity KB of 0.826 μM (KD: 1.1 μM) and ΔH of ?9.8 kcal/mol. GSK2801 or RNAi knockdown of BAZ2A/B with JQ1 selectively displaced BRD2 at promoters/enhancers of ETS-regulated genes. In 2D cultures, enhances displacement of BRD2 from chromatin by combination drug treatment induced senescence. In spheroid cultures, combination treatment induces cleaved caspase-3 and cleaved PARP characteristic of apoptosis in tumor cells. Thus, GSK2801 blocks BRD2-driven transcription in combination with BET inhibitor and induces apoptosis of TNBC.
-
In VivoIn order to determine the suitability of GSK2801 for in vivo experiments, pharmacokinetic parameters after intraperitoneal and oral dosing to male CD1 mice is measured. GSK2801 has reasonable in vivo exposure after oral dosing, modest clearance, and reasonable plasma stability.
-
SynonymsGSK2801 | GSK-2801 | GSK 2801
-
PathwayTyrosine Kinase
-
TargetTAM Receptor
-
RecptorBAZ2A| BAZ2B
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number1619994-68-1
-
Formula Weight371.45
-
Molecular FormulaC20H21NO4S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 50 mg/mL. 134.61 mM; H2O : < 0.1 mg/mL
-
SMILESCCCOc1cc2c(cc(n2cc1)C(=O)C)c1ccccc1S(=O)(=O)C
-
Chemical Name1-(1-(2-(methylsulfonyl)phenyl)-7-propoxyindolizin-3-yl)ethanone
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chen P, et al. J Med Chem. 2015 Apr 6.
molnova catalog
related products
-
ONO-7475
ONO-7475?is an inhibitor with high specificity for anexelekto and MER tyrosine kinase.
-
Ningetinib Tosylate
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
-
Sodium Picosulfate
Sodium Picosulfate inhibits absorption of water and electrolytes, and increases their secretion.
Cart
sales@molnova.com